Month: October 2024

Oct 04 2024

Uncategorized

How does schizophrenia affect smell?

by Clinical Editor

No Comments

Many researchers believe that schizophrenia can affect a person’s ability to smell and how they perceive smells. However, the research is inconclusive.

Oct 04 2024

Uncategorized

Scientists may have found the reason why people with schizophrenia hear voices

by Clinical Editor

No Comments

Scientists now have greater insight into one of Schizophrenia’s poorly understood hallmarks — auditory hallucinations.

Oct 03 2024

Uncategorized

‘Desperate’ families see potential in S.F.’s new mental health court — but few helped so far – San Francisco Chronicle

by Clinical Editor

No Comments

‘Desperate’ families see potential in S.F.’s new mental health court — but few helped so far  San Francisco Chronicle

Oct 03 2024

Uncategorized

I Wish I Had Been Taught About Schizophrenia

by Clinical Editor

No Comments

When I thought of “mental illness,” people who I considered to be “weak” immediately came to mind. I didn’t understand why the mentally ill did not just pull themselves

Oct 02 2024

Uncategorized

Clozapine and Respiratory Infection Risk: What to Know – Medscape

by Clinical Editor

No Comments

Clozapine and Respiratory Infection Risk: What to Know  Medscape

Oct 02 2024

Uncategorized

FDA approves 1st new drug for schizophrenia in more than 30 years

by Clinical Editor

No Comments

The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in more than 30 years.

Oct 01 2024

Uncategorized

Schizophrenia treatment offers alternative with fewer side effects

by Clinical Editor

No Comments

The Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride), making it the first major advancement in schizophrenia treatment in decades.

Oct 01 2024

Uncategorized

Some Parameters of cTBS Reduce Auditory Hallucinations in Schizophrenia

by Clinical Editor

No Comments

Investigators conducted a systematic review and meta-analysis to elucidate the efficacy and safety of cTBS for the treatment of auditory hallucinations in schizophrenia.